// App-Quantinova.ai

359 : No Survival Advantage After Double Umbilical Cord Blood (UCB) Compared to Single UCB Transplant in Children with Hematological Malignancy: Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0501) Randomized Trial

Researchers

Presenter

  • Mary Eapen

Principal Investigators

  • Shelly L Carter

  • Paul R. Haut

  • Edward Peres

  • Kirk R. Schultz

  • Jason Thompson

  • Donna A. Wall

  • Joanne Kurtzberg

Medical Centers

  • British Columbia Childrens Hospital & University of British Columbia, Vancouver, Canada

  • Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada

Locations

  • Canada

Companies

  • Emmes Corporation

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Hematological malignancies

  • Graft-versus-host disease

  • Acute Leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Major Histocompatibility Complex, Class I, A

  • Major histocompatibility complex, class II, DR beta 1

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Mycophenolate mofetil

  • CKD-4101

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Mycophenolic acid

  • Cyclosporine eent

  • fludarabine tablet

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved